

***iLite*[®] IL-23 Assay Ready Cells**

REF: BM4023

For research use only. Not for use in diagnostic procedures.

DESCRIPTION

iLite[®] IL-23 Assay Ready Cells are avian DT-40 cells (ATCC#CRL2111) which have been genetically engineered to be responsive to IL-23, resulting in the specific expression of Firefly Luciferase. Normalization of cell count and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under control of a constitutive promoter.

CONTENT

>250µl of Assay Ready Cells suspended in cryoprotective medium from Amsbio (Cat. No 11910).

RECEIPT AND STORAGE

Upon receipt confirm that adequate dry-ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at least at -80°C or at lower temperature and are stable as supplied until the expiry date shown. Cells should be diluted and plated immediately after thawing.

BACKGROUND

Interleukin 23 (IL-23) is a heterodimeric pro-inflammatory cytokine that shares traits with IL-12. Both cytokines contain the p40 subunit which binds to the receptor chain IL-12Rβ1. However, the two cytokines exert distinct non-redundant biological functions (1). IL-23 has been implicated as an inflammation mediator in several autoimmune diseases and has also been found to promote tumor growth. Therapeutic agents targeting both IL-12 and IL-23 cytokines are currently used to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders (2).

APPLICATION

The *iLite*[®] IL-23 Assay Ready Cells can be used for the quantification of IL-23 or p40 inhibitor activity, or the neutralizing antibody response against such inhibitors in human serum.

Application Notes for the following assays are available:

- Quantification of functional IL-23 (LABEL-DOC-0478)
- Quantification of IL-23 inhibitor activity (LABEL-DOC-0391)
- Determination of neutralizing antibodies against IL-23 inhibitors (LABEL-DOC-0394)

REFERENCES

1. Oppmann B, et. al. *Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.* Immunity 13: 715–25 (2001).
2. Teng MW, Bowman EP, McElwee JJ, Smyth MJ, Casanova JL, Cooper AM, Cua DJ. *IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.* Nature Medicine 21: 719–729 (2015).

SYMBOLS ON LABEL

	Lot number		Temperature limitation
	Catalogue number		Biological risk
	Use by		Manufacturer

PRECAUTIONS

For research use only. This product is intended for professional laboratory research use only. The data and results originating from using the product should not be used either in diagnostic procedures or in human therapeutic applications.

iLite[®] IL-23 Assay Ready Cells are a stable transfected cell line of avian origin classified as a Class 1 Genetically Modified Microorganism. They should be handled in accordance with EU directive (2009/41/EC) and disposed of in a licensed contained-use facility in accordance with these regulations. When used in accordance with the manufacturer’s product specification, the requirements of EC Directive 2009/41/EC on the contained-use of genetically modified microorganisms are deemed to have been met.

Residues of chemicals and preparations generally considered as biohazardous waste should be inactivated prior to disposal by autoclaving or using bleach. All such materials should be disposed of in accordance with established safety procedures.

PROPRIETARY INFORMATION

In accepting delivery of *iLite*[®] Assay Ready Cells the recipient agrees not to sub-culture these cells, attempt to sub-culture them or to give them to a third party, and only to use them directly in assays. *iLite*[®] cell-based products are covered by patents which is the property of Svar Life Science AB and any attempt to reproduce the delivered *iLite*[®] Assay Ready Cells is an infringement of these patents.